Subcategories:

Sort by:

select Language:



NEW World Health Organization model list of essential medicines for children: 7th list

World Health Organization WHO, (2019)


WHO’s Essential Medicines List and List of Essential Diagnostics are core guidance documents that help countries prioritize critical health products that should be widely available and affordable throughout health systems. The updated Essential Medicines List adds 23 medicines for children.
https://apps.who.int/iris/bitstream/handle/10665/3...


NEW World Health Organization Model List of Essential Medicines 21st List

World Health Organization WHO, (2019)


Cancer treatments: While several new cancer treatments have been marketed in recent years, only a few deliver sufficient therapeutic benefits to be considered essential. The 12 medicines WHO added to the new Medicines List for five cancer therapies are regarded as the best in terms of survival rates to treat melanoma, lung, prostate, multiple myeloma and leukemias cancers. For example, two recently developed immunotherapies (nivolumab and pembrolizumab) have delivered up to 50% survival rates for advanced melanoma, a cancer that until recently was incurable. Antibiotics: The Essential Medicines Committee strengthened advice on antibiotic use by updating the AWARE categories, which indicate which antibiotics to use for the most common and serious infections to achieve better treatment outcomes and reduce the risk of antimicrobial resistance. The committee recommended that three new antibiotics for the treatment of multi-drug resistant infections be added as essential. Other updates to the medicines list include: New oral anticoagulants to prevent stroke as an alternative to warfarin for atrial fibrillation and treatment of deep vein thrombosis. These are particularly advantageous for low-income countries as, unlike warfarin, they do not require regular monitoring; Biologics and their respective biosimilars for chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel diseases; Heat-stable carbetocin for the prevention of postpartum haemorrhage. This new formulation has similar effects to oxytocin, the current standard therapy, but offers advantages for tropical countries as it does not require refrigeration
https://apps.who.int/iris/bitstream/handle/10665/3...


NEW Second WHO Model List of Essential In Vitro Diagnostics

World Health Organization WHO, (2019)


The updated List of Essential Diagnostics contains 46 general tests that can be used for routine patient care as well as for the detection and diagnosis of a wide array of disease conditions, and 69 tests intended for the detection, diagnosis and monitoring of specific diseases. The List is divided into two sections depending on the user and setting: one for community settings, which includes self-testing; and a second one for clinical laboratories, which can be general and specialized facilities.
https://www.who.int/medical_devices/publications/S...


NEW Executive summary: the selection and use of essential medicines 2019

World Health Organization WHO, (2019)


Report of the 22nd WHO Expert Committee on the selection and use of essential medicines: WHO Headquarters, Geneva, 1-5 April 2019
https://apps.who.int/iris/bitstream/handle/10665/3...


WHO Model List of Essential Medicines. Several Languages

Wikipedia, (2019)


All WHO essential medicines are covered in Wikipedia: https://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines, and items are translated in several languages. Increasing the amount, quality and languages of information on essential medicines through multiple sources- Wikipedia, formularies, guidelines- will help promoting the use of essential medicines across communities Accessed July 1 ,2019
https://en.wikipedia.org/wiki/WHO_Model_List_of_Es...


Gap analysis: which diseases have treatments on the market or promise in the pipeline?

Access to Medicine Foundation, (2018)


When pharmaceutical companies take action to improve access to medicine, it has the largest impact on their own products. The Access to Medicine Index has identified which products those are – as well as future products still in development – for 20 of the world’s largest research-based pharmaceutical companies
https://accesstomedicinefoundation.org/access-to-m...


Access to Medicines 2018. Fact Sheet

Access to Medicine Foundation, (2018)


The 2018 Access to Medicine Index finds that the pharmaceutical industry continues to mature in its approach to access to medicine, with models for good practice in areas such as access planning and licensing. GSK retains its No. 1 position, as Novartis moves up into 2nd. Takeda rises furthest in 2018, jumping ten places to fifth Download the full report from (Large File 22 MB) https://accesstomedicinefoundation.org/media/uploads/downloads/5c8bc9ceb714b_Access%20to%20Medicine%20Index%202018.pdf
https://accesstomedicinefoundation.org/media/uploa...


Medicines Patents, Access and Innovation

Brot für die Welt, (2016)


The growing challenges for people in low and middle-income countries to access new medicines. Analysis 58
https://www.brot-fuer-die-welt.de/fileadmin/mediap...


Medicines Catalog August 2018

Global Drug Facility, Eds.: World Health Organization WHO, Stop TB, (2018)


The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
http://stoptb.org/assets/documents/gdf/Medicines_C...


47 hits